ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

• Published in: Future oncology (London, England) Vol. 16; no. 10; pp. 517 - 523
• Main Authors: Hillmen, Peter, Brown, Jennifer R, Eichhorst, Barbara F, Lamanna, Nicole, O'Brien, Susan M, Qiu, Lugui, Salmi, Tommi, Hilger, James, Wu, Kenneth, Cohen, Aileen, Huang, Jane, Tam, Constantine S
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.04.2020
• Subjects: Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors; Agammaglobulinaemia Tyrosine Kinase - metabolism; Anemia; Bruton tyrosine kinase; BTK inhibitor; Cardiac arrhythmia; Cardiovascular disease; Chronic Disease; chronic lymphocytic leukemia; clinical trials; Clinical Trials, Phase III as Topic; comparative effectiveness; Diarrhea; Drug dosages; FDA approval; hematologic/leukemia; Humans; Hypertension; ibrutinib; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Lymphatic system; Lymphoma; Neutropenia; Outcome Assessment, Health Care; Piperidines - adverse effects; Piperidines - therapeutic use; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Randomized Controlled Trials as Topic; Risk factors; Safety; Targeted cancer therapy; zanubrutinib; United States > US; ibrutinib; zanubrutinib; Bruton tyrosine kinase; chronic lymphocytic leukemia; hematologic/leukemia; comparative effectiveness; clinical trials; BTK inhibitor
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2019-0844

Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib – a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting.